Stereotactic Radioablation as First-Line Therapy for Scar-Related Ventricular Tachycardia
A legfontosabb adatok
- Ki végzi
- Southlake Health
- Hol
- Newmarket (Kanada)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 20 fő, tervezett
- Kezdés
- 2026. júl.
- Várható befejezés
- 2029. júl.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Stereotactic Arrhythmia Radioablation
- A regiszteradat frissítve
- 2026. június 1.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with scarred heart muscle and a repeated fast heart rhythm called monomorphic ventricular tachycardia (VT). All will get a single targeted dose of radiation to the heart scar as a first treatment.
- Életkor
- 18 years or older
- Nem
- All sexes
- A betegség stádiuma
- Structural heart disease with scar seen on echocardiography, cardiac CT or cardiac MRI. Sustained monomorphic VT in the past 6 months, causing symptoms or needing ICD shocks to stop it.
- Korábbi kezelés
- People who had high-dose radiotherapy before that makes chest radiation unsafe cannot join.
A részvétel fő kizáró okai
- VT with a reversible cause, such as active lack of blood flow to the heart, drugs or salt imbalances in the blood
- Acute coronary syndrome within 30 days, bypass surgery within 90 days, or a stent or other catheter procedure on the heart arteries within 30 days
- Needing chest radiotherapy for an active cancer
- VT source cannot be found or cannot be targeted with radiation, for example several sources
- Pregnant or breast-feeding women
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 years or older and able to provide informed consent
- Structural heart disease with myocardial fibrosis identified on pre-procedural imaging, including imaging evidence of regional myocardial akinesis/thinning or documented scar on echocardiography, cardiac CT, or cardiac MRI
- Sustained monomorphic ventricular tachycardia (symptomatic or requiring ICD shocks for termination) within the previous 6 months
Ki nem vehet részt
- Reversible causes of VT (e.g., active ischemia, drug-induced, electrolyte abnormalities)
- Patients previously treated with high-dose radiotherapy that precludes safe delivery of thoracic stereotactic radiotherapy (relative contraindication)
- Patients who cannot tolerate the radiotherapy treatment position, or whose body habitus is not permissible by treatment bed requirements
- Acute coronary syndrome within 30 days, coronary revascularization (<90 days for bypass surgery, <30 days for percutaneous coronary intervention)
- Patients requiring chest radiotherapy for an active cancer (relative contraindication)
- VT targets cannot be identified or are not suitable for targeting with stereotactic radiotherapy (such as multiple foci of arrhythmia)
- Patients being considered for cardiac transplant who are deemed not eligible by their transplant team for STAR
- Pregnant or breast-feeding women
Helyszínek itt: Kanada
- Southlake Regional Health CentreNewmarket, KanadaContact: Mouhannad Sadek, MDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Ventricular tachycardia (VT) is a dangerous fast heart rhythm originating from scarred areas of the heart muscle, often after a heart attack or in patients with cardiomyopathy. Patients with VT and structural heart disease typically receive an implantable cardioverter-defibrillator (ICD) to prevent sudden death. Despite the ICD, recurrent VT and ICD shocks remain common and are associated with poor quality of life. Current preventive therapies - antiarrhythmic medications and catheter radiofrequency ablation - have important limitations including side effects, incomplete effectiveness, and procedural risk.
A teljes eredeti leírásKevesebb
Stereotactic Arrhythmia Radioablation (STAR) is a non-invasive treatment in which a single, precisely targeted dose of radiation is delivered to the scar tissue that gives rise to the abnormal heart rhythm. STAR has previously been studied in patients who have failed catheter ablation or are too high risk for that procedure, with promising results. However, STAR has not been formally evaluated as a first-line treatment.
This single-arm prospective feasibility study will enroll 20 adults with structural heart disease and sustained monomorphic VT. Each participant will receive a single 25 Gy fraction of stereotactic body radiotherapy (VMAT technique) targeted at the arrhythmogenic substrate identified by cardiac imaging, 12-lead ECG, and (where available) non-invasive electrocardiographic mapping or electroanatomical mapping. Participants will be followed at 6 weeks, 3, 6, 9, and 12 months to assess the primary efficacy outcomes (death, appropriate ICD shock, VT storm, and sustained VT below ICD detection rate after a 6-week blanking period) and safety outcomes (acute heart failure decompensation, drop in left ventricular ejection fraction, and STAR-specific toxicities such as pneumonitis, esophagitis, and pericarditis). The hypothesis is that STAR delivered as first-line therapy is safe and effective, with a comparable toxicity and efficacy profile to catheter radiofrequency ablation.
A vizsgálat csoportja
- STAR (Stereotactic Arrhythmia Radioablation)A vizsgált kezelés
Single 25 Gy fraction of VMAT-based stereotactic body radiotherapy delivered to the arrhythmogenic substrate identified by cardiac CT, 12-lead ECG of the clinical arrhythmia, and (where available) non-invasive electrocardiographic mapping or electroanatomical mapping. In selected cases with large planning target volumes or proximity to organs at risk, the dose may be delivered in 2 fractions 24-48 hours apart. Participants are followed for 12 months for arrhythmia outcomes and radiation toxicity.
Kezelés: Stereotactic Arrhythmia Radioablation
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Stereotactic Arrhythmia Radioablation as First-Line Treatment for Scar-Related Ventricular Tachycardia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. június 1.